Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt

January 3, 2021 updated by: Aliae AR Mohamed Hussein, Assiut University

A National Survey of Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt

The COVID-19 pandemic is expected to remain as a public health threat and economic burden all over the world. The available proposed vaccines are still lacking large randomized controlled trials testing its efficacy and safety. Thus, the acceptance of vaccination between citizens as well as healthcare workers is not guaranteed. As the vaccine is starting to be distributed the acceptance of healthcare givers should be measured as they are usually the front line facing the problem and they have a responsibility to explain the need of immunization to the rest of population.

Strategies to enhance the acceptance and trust of the available vaccines may be needed.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Assiut, Egypt, 71111
        • Recruiting
        • AssiutU
        • Contact:
      • Assiut, Egypt, 71515
        • Recruiting
        • Aliae AR Mohamed-Hussein

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Participants were recruited by Consensus Strategies through online survey to avoid coverage bias.

Doctors, nurses, laboratory workers and radiology technicians were included

Description

Inclusion Criteria: Healthcare workers

-

Exclusion Criteria:

  • None healthcare workers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure frequency of acceptance of vaccination
Time Frame: 6 months
number of healthcare worker agreeing to take the vaccine
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Describe causes of refusal of vaccination
Time Frame: 6 months
answer a questionnaire of the causes of avoidance of vaccine
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2020

Primary Completion (Anticipated)

January 30, 2021

Study Completion (Anticipated)

February 15, 2021

Study Registration Dates

First Submitted

December 20, 2020

First Submitted That Met QC Criteria

January 3, 2021

First Posted (Actual)

January 5, 2021

Study Record Updates

Last Update Posted (Actual)

January 5, 2021

Last Update Submitted That Met QC Criteria

January 3, 2021

Last Verified

December 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

3
Subscribe